Adding the T-Cell Booster Decitabine to Anti –PD-1 Therapy in Hodgkin Lymphoma

Researchers tested the addition of the T cell –boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.

Source: CancerNetwork - May 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news